Jiangsu Cancer Hospital
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT07367516 | |
| PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer | Gastric or Esophagogastric Junction Adenocarcinoma | Active, not recruiting | Phase 3 | 2026-07-07 | NCT05180734 | |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | cancer, neoplasm | Active, not recruiting | Phase 3 | 2026-07-07 | NCT04464226 | |
| A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT05170958 | |
| A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract cancer, biliary tract disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-08 | NCT06431490 | |
| A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs | HER2 IHC3+ Advanced Colorectal Cancer | Not yet recruiting | Phase 3 | 2026-03-19 | NCT07483684 | |
| Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C | Advanced Pancreatic Cancer | Recruiting | Phase 1 / Phase 2 | 2026-03-10 | NCT06821503 | |
| Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study | Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent | Recruiting | Phase 2 | 2025-12-31 | NCT07311577 | |
| TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer | RAS/BRAF Wild Type Colorectal Cancer | Recruiting | Phase 1 / Phase 2 | 2025-08-12 | NCT07044908 | |
| A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2025-06-10 | NCT05346224 | |
| QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, malignant tumor of nasopharynx, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 3 | 2025-05-22 | NCT06749899 | |
| Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | C-Met Exon 14 Mutation | Recruiting | Phase 1 / Phase 2 | 2022-08-01 | NCT04270591 |